Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide
2. Kmd 3213
3. Kmd-3213
4. Rapaflo
1. 160970-54-7
2. Rapaflo
3. Urief
4. Silodyx
5. Urorec
6. Kmd-3213
7. Kmd 3213
8. Rapilif
9. Silodal
10. Kad 3213
11. Kad-3213
12. Kso-0400
13. Cuz39luy82
14. Chembl24778
15. 1-(3-hydroxypropyl)-5-[(2r)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
16. 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1h-indole-7-carboxamide
17. (-)-1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1h-indole-7-carboxamide
18. Rapflo
19. Silodosin [inn]
20. ( C)-1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1h-indole-7-carboxamide
21. (-)-1-(3-hydroxypropyl)-5-((2r)-2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)-2,3-dihydro-1h-indole-7-carboxamide
22. 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carboxamide
23. 1h-indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-
24. Silodosin [inn:ban]
25. Unii-cuz39luy82
26. Urief, Rapaflo
27. 2,3-dihydro-1-(3-hydroxypropyl)-5-((2r)-2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)-1h-indole-7-carboxamide
28. Rapaflo (tn)
29. Silodosin (rapaflo)
30. Urief (tn)
31. Silodosin (r-isomer)
32. Silodosin [jan]
33. Silodosin [mi]
34. Silodosin [vandf]
35. Silodosin (jp17/inn)
36. Silodosin [mart.]
37. Silodosin [who-dd]
38. Gtpl493
39. Silodosin [ema Epar]
40. Mls006010022
41. Schembl136973
42. Silodosin [orange Book]
43. Silodosin, >=98% (hplc)
44. Dtxsid40167045
45. Kmd3213
46. Chebi:135929
47. Hms3715b06
48. Hms3884o21
49. Bcp02143
50. Zinc3806063
51. Bdbm50160154
52. Mfcd00930170
53. S1613
54. Akos005145899
55. Kad 3213;kmd 3213
56. Bs-1011
57. Ccg-221202
58. Cs-0284
59. Db06207
60. Ncgc00345882-03
61. 1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide
62. Ac-22605
63. Hy-10122
64. Smr004701206
65. Am20090780
66. I1128
67. Sw219765-1
68. D01965
69. 970s649
70. A810210
71. Q411770
72. Sr-01000944157
73. Q-102517
74. Sr-01000944157-1
75. (r)-1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide
76. (r)-5-[2-[[2-[2-(2,2,2-trifluoro-ethoxy)phenoxy]ethyl]amino]propyl]-1-(3-hydroxypropyl)-2,3-dihydro-1h-indole-7-carboxamide
77. 1-(3-hydroxy-propyl)-5-((r)-2-{2-[2-(2,2,2-trifluoro-ethoxy)-phenoxy]-ethylamino}-propyl)-2,3-dihydro-1h-indole-7-carboxylic Acid Amide
78. 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]-ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carboxamide
79. 1-(3-hydroxypropyl)-5-[(2r)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1h-indole-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2r)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carboxamide; (-)-1
| Molecular Weight | 495.5 g/mol |
|---|---|
| Molecular Formula | C25H32F3N3O4 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 13 |
| Exact Mass | 495.23449100 g/mol |
| Monoisotopic Mass | 495.23449100 g/mol |
| Topological Polar Surface Area | 97 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 654 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Rapaflo |
| PubMed Health | Silodosin (By mouth) |
| Drug Classes | Benign Prostatic Hypertrophy Agent |
| Drug Label | RAPAFLO is the brand name for silodosin, a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide... |
| Active Ingredient | Silodosin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 8mg; 4mg |
| Market Status | Prescription |
| Company | Watson Labs |
| 2 of 2 | |
|---|---|
| Drug Name | Rapaflo |
| PubMed Health | Silodosin (By mouth) |
| Drug Classes | Benign Prostatic Hypertrophy Agent |
| Drug Label | RAPAFLO is the brand name for silodosin, a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide... |
| Active Ingredient | Silodosin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 8mg; 4mg |
| Market Status | Prescription |
| Company | Watson Labs |
Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It is not indicated for the treatment of hypertension.
FDA Label
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.
Silodosin is an antagonist of 1-adrenoceptors. It has the highest selectivity for the 1A-adrenoceptor subtype, with a 162-fold greater affinity than 1B-adrenoceptor and about a 50-fold greater affinity than for 1D-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia. Following oral administration, silodosin had a rapid onset of effect in men, with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose. Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects. As with all 1-adrenoceptor antagonists blocking 1-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking 1-AR antagonists.
Adrenergic alpha-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04CA04
G04CA04
G04CA04
G04CA04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G04 - Urologicals
G04C - Drugs used in benign prostatic hypertrophy
G04CA - Alpha-adrenoreceptor antagonists
G04CA04 - Silodosin
Absorption
The absolute bioavailability is approximately 32%. Following oral administration of silodosin 8 mg once daily in healthy male subjects, Cmax was 61.6 27.54 ng/mL and AUC was 373.4 164.94 ng x hr/mL. The Tmax was 2.6 0.90 hours. Silodosin glucuronide or KMD-3213G, the main metabolite of silodosin, has an AUC three- or four fold higher than for the parent compound. A moderate fat or calorie meal reduces Cmax by 18% to 43% and AUC by 4% to 49%, as well as Tmax by about one hour. However, the US prescribing information recommends drug intake with meals to avoid the potential adverse effects associated with high plasma drug concentrations.
Route of Elimination
At 10 days following oral administration of radiolabelled silodosin, about 33.5% of the dose was recovered in urine and 54.9% was recovered in feces.
Volume of Distribution
Silodosin has an apparent volume of distribution of 49.5 L.
Clearance
After intravenous administration, the plasma clearance of silodosin was approximately 10 L/hour.
The main metabolite of silodosin is silodosin glucuronide (KMD-3213G), which is a pharmacologically active metabolite formed by direct glucuronide conjugation mediated by UDP-glucuronosyltransferase 2B7 (UGT2B7). Silodosin glucuronide reaches plasma exposure (AUC) approximately four times greater than that of silodosin. The second major metabolite, KMD-3293, is formed from dehydrogenation catalyzed by alcohol and aldehyde dehydrogenases. KMD-3293 has negligible pharmacological activity and reaches plasma exposures similar to that of silodosin. Silodosin is also metabolized by CYP3A4, which catalyzes the oxidation reaction. Other than glucuronidation, dehydrogenation, and oxidation as its main metabolic pathways, silodosin can also undergo dealkylation (KMD-3289), N-dealkylation, hydroxylation, glucosylation, and sulfate conjugation. Metabolites of silodosin can undergo a series of further metabolic pathways.
The elimination half-life of silodosin is 13.3 8.07 hours. KMD-3213G, the main metabolite of silodosin, has an extended half-life of approximately 24 hours.
The pathogenesis of benign prostatic hyperplasia is not fully understood: it is believed to involve several pathways, including inflammation, apoptosis, and cellular proliferation. Most drug therapies aim to alleviate symptoms of benign prostatic hyperplasia, silodosin included. Lower urinary tract symptoms of benign prostatic hyperplasia are categorized into three main groups: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Prostate contraction is the main contributor to lower urinary tract symptoms of benign prostatic hyperplasia. The smooth muscle tone of the prostate is regulated by 1A-adrenoceptors, which are the most highly expressed subtype of 1adrenoceptors in the human prostate tissue. It has been reported that blockade of 1A-adrenoceptors relieves bladder outlet obstruction. Blockade of 1D-adrenoceptors, another subtype found in prostate tissue, is believed to alleviate storage symptoms due to detrusor overactivity. 1-adrenoceptors are G protein-coupled receptors: upon binding of its natural ligand, norepinephrine and epinephrine, leads to the activation of phospholipase C and downstream signalling molecules, including inositol triphosphate and diacylglycerol. Ultimately, there is an increase in intracellular calcium levels and, consequently, smooth muscle contraction. Silodosin is an antagonist of 1-adrenoceptors, with the highest selectivity for the 1A-adrenoceptor subtype. By blocking the 1A-adrenoceptor signalling pathway, silodosin promotes prostatic and urethral smooth muscle relaxation, thereby improving lower urinary tract symptoms such as voiding. Silodosin also targets afferent nerves in the bladder, relieving bladder overactivity and storage symptoms.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE;ORAL - 4MG
USFDA APPLICATION NUMBER - 22206
DOSAGE - CAPSULE;ORAL - 8MG
USFDA APPLICATION NUMBER - 22206
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
100
PharmaCompass offers a list of Silodosin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Silodosin manufacturer or Silodosin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Silodosin manufacturer or Silodosin supplier.
PharmaCompass also assists you with knowing the Silodosin API Price utilized in the formulation of products. Silodosin API Price is not always fixed or binding as the Silodosin Price is obtained through a variety of data sources. The Silodosin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Urorec manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Urorec, including repackagers and relabelers. The FDA regulates Urorec manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Urorec API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Urorec manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Urorec supplier is an individual or a company that provides Urorec active pharmaceutical ingredient (API) or Urorec finished formulations upon request. The Urorec suppliers may include Urorec API manufacturers, exporters, distributors and traders.
click here to find a list of Urorec suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Urorec DMF (Drug Master File) is a document detailing the whole manufacturing process of Urorec active pharmaceutical ingredient (API) in detail. Different forms of Urorec DMFs exist exist since differing nations have different regulations, such as Urorec USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Urorec DMF submitted to regulatory agencies in the US is known as a USDMF. Urorec USDMF includes data on Urorec's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Urorec USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Urorec suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Urorec Drug Master File in Japan (Urorec JDMF) empowers Urorec API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Urorec JDMF during the approval evaluation for pharmaceutical products. At the time of Urorec JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Urorec suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Urorec Drug Master File in Korea (Urorec KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Urorec. The MFDS reviews the Urorec KDMF as part of the drug registration process and uses the information provided in the Urorec KDMF to evaluate the safety and efficacy of the drug.
After submitting a Urorec KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Urorec API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Urorec suppliers with KDMF on PharmaCompass.
A Urorec written confirmation (Urorec WC) is an official document issued by a regulatory agency to a Urorec manufacturer, verifying that the manufacturing facility of a Urorec active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Urorec APIs or Urorec finished pharmaceutical products to another nation, regulatory agencies frequently require a Urorec WC (written confirmation) as part of the regulatory process.
click here to find a list of Urorec suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Urorec as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Urorec API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Urorec as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Urorec and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Urorec NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Urorec suppliers with NDC on PharmaCompass.
Urorec Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Urorec GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Urorec GMP manufacturer or Urorec GMP API supplier for your needs.
A Urorec CoA (Certificate of Analysis) is a formal document that attests to Urorec's compliance with Urorec specifications and serves as a tool for batch-level quality control.
Urorec CoA mostly includes findings from lab analyses of a specific batch. For each Urorec CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Urorec may be tested according to a variety of international standards, such as European Pharmacopoeia (Urorec EP), Urorec JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Urorec USP).
